

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 10

Complete if Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk et al.
Group Art Unit	1632 K647
Examiner Name	Not Yet Assigned Nichols

Attorney Docket Number 15270J-005912US

DEC 11 2001

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
OCT 11 2001

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
CSN	196	6,150,091		Pandolfo et al.	11-21-2000	_____
CSN	1	6,057,367		Stamler et al.	05-02-2000	_____
CSN	2	5,958,883		Snow	09-28-1999	_____
CSN	3	5,955,317		Suzuki et al.	09-21-1999	_____
CSN	4	5,955,079		Mond et al.	09-21-1999	_____
CSN	5	5,877,399		Hsiao et al.	03-02-1999	_____
CSN	6	5,869,093		Weiner et al.	02-09-1999	_____
CSN	7	5,869,054		Weiner et al.	02-09-1999	_____
CSN	8	5,854,204		Findeis et al.	12-29-1998	_____
CSN	9	5,851,996		Kline	12-22-1998	_____
CSN	10	5,849,298		Weiner et al.	12-15-1998	_____
CSN	11	5,837,473		Maggio et al.	11-17-1998	_____
CSN	12	5,786,180		Konig et al.	07-28-1998	_____
JI	207	5,780,587		Potter	07-14-1998	_____
CSN	13	5,753,624		McMichael et al.	05-19-1998	_____
CSN	14	5,750,349		Suzuki et al.	05-12-1998	_____
CSN	197	5,744,368		Goldgaber et al.	04-28-1998	_____
CSN	211	5,736,142		Sette et al.	04-07-1998	_____
CSN	15	5,733,547		Weiner et al.	03-31-1998	_____
CSN	16	5,688,651		Solomon	11-18-1997	_____
	17	5,679,348		Nesburn et al.	10-21-1997	_____
	18	5,645,820		Hafler et al.	07-08-1997	_____
	19	5,641,474		Hafler et al.	06-24-1997	_____
	20	5,641,473		Hafler et al.	06-24-1997	_____
	21	5,612,486		McConlogue et al.	03-18-1997	_____
	22	5,605,811		Seubert et al.	02-25-1997	_____
	23	5,585,100		Mond et al.	12-17-1996	_____
	24	5,571,500		Hafler et al.	11-05-1996	_____
	25	5,571,499		Hafler et al.	11-05-1996	_____
	175	5,441,870		Seubert, et al.	08-15-1995	_____
	26	5,434,170		Andrusis, Jr.	07-18-1995	_____
	27	5,387,742		Cordell	02-07-1995	_____
	181	5,270,165		Van Nostrand et al.	12-14-1993	_____
	28	5,231,000		Majocha et al.	07-27-1993	_____
	29	5,220,013		Ponte et al.	06-15-1993	_____
	30	5,208,036		Eppstein et al.	05-04-1993	_____
	31	5,192,753		McGeer et al.	03-09-1993	_____

Examiner Signature

John S.

Date Considered

11/15/02

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3189626 v1

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 10

Complete if Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk et al.
Group Art Unit	1692-1647
Examiner Name	Not Yet Assigned Nichols
Attorney Docket Number	15270J-005912US

DEC 11 2001
U.S. PATENT AND TRADEMARK OFFICE

202	PCT	97/21728	A1	06-19-1997		
62	PCT	97/17613	A1	05-15-1997		
63	PCT	96/39176	A1	12-12-1996		
208	PCT	96/28471	A1	09-19-1996		
64	PCT	96/25435	A1	08-22-1996		
65	PCT	96/18900	A1	06-20-1996		
66	PCT	95/31996	A1	11-30-1995		
200	PCT	95/12815	A1	05-11-1995		
67	PCT	95/11994	A1	05-04-1995		
68	PCT	95/11311	A1	04-27-1995		
69	PCT	95/05853	A1	03-02-1995		
70	PCT	95/04151	A2	02-09-1995		
201	PCT	94/28412	A1	12-08-1994		
71	PCT	94/03615	A1	02-17-1994		
72	PCT	94/01772	A1	01-20-1994		
73	PCT	93/21950	A1	11-11-1993		
74	PCT	93/16724	A1	09-02-1993		
75	PCT	93/15760	A1	08-19-1993		
76	PCT	93/14200	A1	07-22-1993		
205	PCT	93/04194	A1	03-04-1993		
77	PCT	93/02189	A1	02-04-1993		
78	PCT	92/13069	A1	08-06-1992		
79	PCT	92/06708	A1	04-30-1992		
80	PCT	92/06187	A1	04-16-1992		
81	PCT	91/19810	A1	12-26-1991		
82	PCT	91/16819	A1	11-14-1991		
83	PCT	91/12816	A1	09-05-1991		
84	PCT	91/08760	A1	06-27-1991		
85	PCT	90/12871	A1	11-01-1990		
86	PCT	90/12870	A1	11-01-1990		
87	PCT	89/01343	A1	02-23-1989		
88	PCT	89/06242	A1	07-13-1989		
89	PCT	89/06689	A1	07-27-1989		
90	PCT	89/03687	A1	05-05-1989		
91	PCT	88/10120	A1	12-29-1988		
92	GB	2 220 211	A	01-04-1990		
93	GB	2 335 192	A	09-15-1999		

Examiner
Signature

Date
Considered

11/01/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/088 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of 10

Complete if Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk et al.
Group Art Unit	1632 <i>Adft</i>
Examiner Name	Not Yet Assigned <i>Nichols</i>
Attorney Docket Number	15270J-005912US

DEC 11 2001
U.S. PATENT AND TRADEMARK OFFICE
O I P E

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>Cyo</i>	94	ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?", <i>Neurology</i> , 45:1441-1445 (1995).	<input type="checkbox"/>
<i>Cyo</i>	95	Associated Press, "Immune cells may promote Alzheimer's, a study finds," <i>The Boston Globe</i> (4/13/95).	<input type="checkbox"/>
<i>Cyo</i>	96	BAUER et al., "Interleukin-6 and α -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <i>FEBS Letters</i> , 285(1):111-114 (1991).	<input type="checkbox"/>
<i>gmc</i>	204	BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," <i>Eur. J. Immunol.</i> 29:345-354 (1999).	<input type="checkbox"/>
<i>gmc</i>	212	BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," <i>Soc. for Neuroscience Abstracts</i> 18:764 (1992).	<input type="checkbox"/>
<i>gmc</i>	176	BARD et al., "Peripherally administered antibodies against amyloid β -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <i>Nature Medicine</i> , 6(8):916-919 (2000).	<input type="checkbox"/>
<i>Cyo</i>	97	BLASS, John P., "Immunologic Treatment of Alzheimer's Disease," <i>New England J. Medicine</i> , 341(22):1694 (1999).	<input type="checkbox"/>
<i>Cyo</i>	98	BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <i>Biochem. Biophys. Res. Comm.</i> , 171(2):890-897 (1990).	<input type="checkbox"/>
<i>Cyo</i>	99	BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," <i>Neuron</i> , 19: 939-945 (1997).	<input type="checkbox"/>
<i>gmc</i>	100	BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," <i>Cur. Opin. Genet. Develop.</i> , 3: 102-109 (1993).	<input type="checkbox"/>
<i>gmc</i>	101	BRICE et al., "Absence of the amyloid precursor protein gene mutation (APP717 : Val->Ile) in 85 cases of early onset Alzheimer's disease," <i>J. Neurology, Neurosurg. Psychiatry</i> , 56:112-115 (1993).	<input type="checkbox"/>
<i>gmc</i>	102	CHAO et al., "Transforming Growth Factor- β Protects human Neurons Against β -Amyloid-Induced Injury," <i>Soc. Neurosci. Abstracts</i> , 19:513.7 (1993).	<input type="checkbox"/>
<i>gmc</i>	213	CHEN et al. "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," <i>Neuroscience Letters</i> 125:223-226 (1991).	<input type="checkbox"/>
<i>gmc</i>	214	DEMATTOS et al., "Peripheral Anti A β Antibody Alters CNS And Plasma A β Clearance and Decreases Brain A β Burden in a Mouse Model of Alzheimer's Disease," <i>Proc. Natl. Acad. Sci. USA</i> , 101:1073/pnas.151261398 (2001).	<input type="checkbox"/>
<i>gmc</i>	103	DUFF et al., "Mouse model made," <i>Nature</i> , 373: 476-477 (1995).	<input type="checkbox"/>

Examiner Signature	<i>G. Michael Nichols</i>	Date Considered	11/15/02
--------------------	---------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

+

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3189626 v1

Substitute for form 1449A/PTO


INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 10

Complete if Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk et al.
Group Art Unit	1632 K617
Examiner Name	Not Yet Assigned Nichols
Attorney Docket Number	15270J-005912US



104	ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J. Neurol. Sciences</u> , 59:341-347 (1983).
105	FELSENSTEIN et al., "Processing of the β -amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <u>Neuroscience Letters</u> , 152:185-189 (1993).
106	FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," <u>Neurobiology of Aging</u> , 17(5):809-815 (1996).
107	FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <u>PNAS</u> , 88:1779-1782 (1991).
108	FLANDERS et al., "Altered expression of transforming growth factor- β in Alzheimer's disease," <u>Neurology</u> , 45:1561-1569 (1995).
210	FRIEDLAND et al., "Development of an anti-A β monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," <u>Mol. Neurology</u> , 9:107-113 (1994).
109	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein," <u>Nature</u> , 373(6514): 523-527 (1995).
215	GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with A β ₁₋₄₂ ," <u>Annals of the New York Academy of Science</u> 920:274-84 (2000).
110	GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TIPS</u> , 13:108-113 (1992).
111	GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <u>J. Exp. Med.</u> , 177:1181-1186 (1993).
112	GLENN et al., "Skin immunization made possible by cholera toxin," <u>Nature</u> , 391: 851 (1998).
113	GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochemical and Biophysical Research Communications</u> , 120(3): 885-890 (1994).
114	GLENNER et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochemical and Biophysical Research Communications</u> , 122(3): 1131-1135 (1984).
115	GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <u>Nature</u> , 349:704-706 (1991).
116	GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," <u>PNAS</u> , 93:427-432 (1996).
190	GRAVINA et al., "Amyloid β Protein (A β) in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 270(13):7013-7016 (1995).
117	GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," <u>Vaccine</u> , 15(12/13): 1341-1343 (1997).
118	HAGA et al., "Synthetic Alzheimer amyloid β /A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Research</u> , 601:88-94 (1993).

Examiner
SignatureDate
Considered

11/15/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3189626 v1

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 10

C mplete if Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk et al.
Group Art Unit	1632-1617
Examiner Name	Not Yet Assigned Nichols
Attorney Docket Number	15270J-005912US

DEC 11 2001

TRADEMAKS & DESIGN

grw	119	HANES et al., "New advances in microsphere-based single-dose vaccines," <u>Advanced Drug Delivery Reviews</u> , 28: 97-119 (1997).	—
grw	120	HARDY, "Amyloid, the presenilins and Alzheimer's disease," <u>TINS</u> , 20(4): 154-159 (1997).	—
grw	121	HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," <u>Annals of Med.</u> , 28:255-258 (1996).	—
grw	193	HARRINGTON et al., "Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein," <u>Biochimica Biophysica Acta</u> , 1158:120-128 (1993).	—
grw	177	HELMUTH, L., "Further Progress on a β -Amyloid Vaccine," <u>Science</u> , 289:375 (2000).	—
grw	122	HSIAO et al., "Correlative Memory Deficits, $\text{A}\beta$ Elevation, and Amyloid Plaques in Transgenic Mice," <u>Science</u> , 274: 99-102 (1996).	—
grw	123	HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J. Neuroimmunology</u> , 52:147-152 (1994).	—
grw	124	HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," <u>N. E. J. Medicine</u> , 333(19):1283-1284 (1995).	—
grw	125	ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J. Neuroimmunology</u> , 24:173-182 (1989).	—
grw	192	IWATSUBO et al., "Visualization of $\text{A}\beta$ 42(43) and $\text{A}\beta$ 40 in Senile Plaques with End-Specific $\text{A}\beta$ Monoclonals: Evidence That an Initially Deposited Species Is $\text{A}\beta$ 42(43)," <u>Neuron</u> , 13:45-53 (1994).	—
grw	126	JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <u>Immun. Rev.</u> , 62: 185-216 (1982).	—
grw	216	JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <u>Am. J. of Pathology</u> 138:373-378 (1991).	—
grw	127	KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <u>Res. Immunology</u> , 143:637-641 (1992).	—
grw	183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <u>Biotechnol. Appl. Biochem.</u> , 23:227-230 (1996).	—
grw	128	KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <u>Nature</u> , 354:476-478 (1991).	—
grw	195	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the β A4 Peptide," <u>Annals of NY Acad. Sci.</u> , 777:344-355 (1996).	—
grw	129	LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <u>Neurodegeneration</u> , 2:111-121 (1993).	—
grw	130	LANGER, "New Methods of Drug Delivery," <u>Science</u> , 249: 1527-1532 (1990).	—

Examiner Signature	<i>grw</i>	Date Considered	11/15/02
--------------------	------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3189626 v1

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 10

Complete if Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk et al.
Group Art Unit	1692-K47
Examiner Name	Not Yet Assigned Nichols

Attorney Docket Number 15270J-005912US



gn	131	LANNFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behavioural Brain Res.</u> , 57:207-213 (1993).
gn	132	LEMERÉ et al., "Mucosal Administration of A β Peptide Decreases Cerebral Amyloid Burden In Pd-App Transgenic Mice," <u>Society for Neuroscience Abstracts</u> , vol. 25, part I, Abstract 519.6, 29th Annual Meeting, (October 23-28, 1999).
gn	133	LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," <u>J. Immunol.</u> , 159: 1383-1392 (1997).
gn	134	LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," <u>Acta. Neurol. Scand.</u> , 84:441-444 (1991).
gn	218	MAJOCHA et al., "Development of a Monoclonal Antibody Specific for β /A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," <u>The J. of Nuclear Med.</u> , 33:2184-2189 (1992).
gn	217	MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," <u>Proc. Natl. Acad. Sci. USA</u> , 82:4245-4249 (1985).
gn	135	MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <u>J. Micro. Encap.</u> , 14(2): 197-210 (1997).
gn	136	MEDA et al., "Activation of microglial cells by β -amyloid protein and interferon- γ ," <u>Nature</u> , 374:647-650 (1995).
gn	137	MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J. Exp. Med.</u> , 174:791-798 (1991).
gn	206	MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 267(24):17082-17088 (1992).
gn	191	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am. J. Pathology</u> , 144(5):1082-1088 (1994).
gn	138	NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," <u>Am. J. Epidemiol.</u> , 145(11): 959-969 (June 1, 1997).
gn	139	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).
gn	140	PARESCHE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," <u>Neuron</u> , 17:553-565 (September 1996).
gn	141	PAUL et al., "Transdermal immunization with large proteins by means of ultra deformable drug carriers," <u>Eur. J. Immunol.</u> , 25: 3521-3524 (1995).
gn	142	PRIEELS et al., "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 86406t (1994).
gn	143	QUON et al., "Formation of β -Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> , 352:239-241 (1991).
	144	+RAG, V.A., Grant application # 1 R10 AGL5746-01 (publication date unknown)

Examiner Signature	<i>G. Miles</i>	Date Considered	11/15/02
--------------------	-----------------	-----------------	----------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3189626 v1

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 10

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk et al.
Group Art Unit	1632-KAT
Examiner Name	Not Yet Assigned <i>Nichols</i>

Attorney Docket Number 15270J-005912US

O I P E
DEC 11 2001
P A D D E R I A F C E

<i>gn</i>	145	RASO, "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , Abstract (April 2, 1998).	—
<i>gn</i>	146	ROGERS et al., "Complement activation by β -amyloid in Alzheimer Disease," <u>PNAS</u> , 89:1-5 (1992).	—
<i>gn</i>	147	ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Annals of New York Academy of Sciences</u> , 695:198-202 (1993).	—
<i>gn</i>	209	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1978).	—
<i>gn</i>	189	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <u>J. Biol. Chem.</u> , 268(33):25239-25243 (1993).	—
<i>gn</i>	194	SAIDO et al., "Spatial Resolution of the Primary β -Amyloidogenic Process Induced in Postischemic Hippocampus," <u>J. Biol. Chem.</u> , 269(21):15253-15257 (1994).	—
<i>gn</i>	178	SCHENK et al., "Therapeutic Approaches Related to Amyloid- β Peptide and Alzheimer's Disease," <u>J. Med. Chem.</u> , 38(21):4141-4154 (1995).	—
<i>gn</i>	148	SCHENK et al., "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999).	—
<i>gn</i>	149	SELKOE, D.J., "Imaging Alzheimer's Amyloid," <u>Nat. Biotech.</u> , 18:823-824 (2000).	—
<i>gn</i>	150	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <u>J. Neuropathol. Exp. Neurol.</u> , 53(5): 438-447 (1994).	—
<i>gn</i>	151	SELKOE, "Physiological production of the β -amyloid protein and the mechanism of Alzheimer's disease," <u>Trends in Neurosciences</u> , 16(10): 403-409 (1993).	—
<i>gn</i>	152	SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease.....," <u>Scientific American</u> , pgs. 68-78 (November, 1991).	—
<i>gn</i>	153	SELKOE, Dennis J., "In the Beginning...." <u>Nature</u> , 354:432-433 (1991).	—
<i>gn</i>	154	SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," <u>Neuron</u> , 6:487-498 (1991).	—
<i>gn</i>	155	SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:630-631 (1997).	—
<i>gn</i>	156	SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids," <u>Nature</u> , 359: 325-327 (1992).	—
<i>gn</i>	157	SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," <u>Neuroscience Res.</u> , 13:237-255 (1992).	—
<i>gn</i>	158	SMITS et al., "Prion Protein and Scrapie Susceptibility," <u>Vet. Quart.</u> , 19(3): 101-105 (1997).	—

Examiner Signature	<i>G. M. Nichols</i>	Date Considered	11/15/02
--------------------	----------------------	-----------------	----------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3189626 v1

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 10

Complete if Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk et al.
Group Art Unit	1632 1647
Examiner Name	Not Yet Assigned Nichols
Attorney Docket Number	15270J-005912US

DEC 11 2001

gn	159	SOLOMON et al., "Disaggregation of Alzheimer β -amyloid by site-directed mAb," <i>PNAS</i> , 94:4109-4112 (1997).
gnw	160	SOLOMON et al., "Monoclonal antibodies inhibit <i>in vitro</i> fibrillar aggregation of the Alzheimer β -amyloid peptide," <i>PNAS</i> , 93:452-455 (1996).
gnw	161	SOLOMON, A., "Pro-Rx (Protein Therapeutics)," University of Tennessee Medical Center (publication date unknown).
	162	SOLOMON, B., "New Approach Towards Fast Induction of Anti β -Amyloid Peptide Immune Response," <i>Department of Molecular Microbiology & Biotechnology, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel</i> (publication date unknown).
gn	182	SOLOMON et al., "Inhibitory effect of monoclonal antibodies on Alzheimer's β -amyloid peptide aggregation," <i>Int. J. Exp. Clin. Invest.</i> , 3:130-133 (1996).
gnw	184	SOLOMON et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <i>Biochem. Mol. Biol. Int.</i> , 43(3):601-611 (1997).
gnw	185	SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <i>Adv. Mol. Cell Biology</i> , 15A:33-45 (1996).
	186	SOLOMON et al., "Activity of monoclonal antibodies in prevention of <i>in vitro</i> aggregation of their antigens," <i>abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel</i> (publication date unknown).
gnw	179	SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," <i>J. Neurochemistry</i> , 66:259-265 (1996).
gnw	163	STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum Malaria</i> ," <i>N. Engl. J. Med.</i> , 336(2): 86-91 (1997).
gn	164	STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <i>PNAS</i> , 94: 13287-13292 (1997).
gnw	165	TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <i>European J. Pharmacology</i> , 352:135-142 (1998).
gnw	166	TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <i>Immunobiology</i> , 191(2-3):114-115 Abstract C.37, (1994).
gnw	167	VAN GOOL et al., "Concentrations of amyloid- β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <i>Neuroscience Letters</i> , 172:122-124 (1994).
gn	168	VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <i>Amer. Journ. Pathology</i> , 144(1):104-116 (1994).
gnw	169	WALKER et al., "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <i>J. Neuropath. Exp. Neurology</i> , 53(4):377-383 (1994).
gn	180	WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <i>Annu. Rev. Immunol.</i> , 12:809-837 (1994).
gnw	170	WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," <i>Curr. Opin. Neurobiol.</i> , 7: 695-700 (1997).

Examiner Signature	<i>G. Meier</i>	Date Considered	11/15/02
--------------------	-----------------	-----------------	----------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3189626 v1

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

10

of

10

Complete if Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk et al.
Group Art Unit	1602- 1647
Examiner Name	Not Yet Assigned <i>Michols</i>
Attorney Docket Number	15270J-005912US

<i>GW</i>	171	WEN, G.Y., "Alzheimer's Disease and Risk Factors," <i>J. Food Drug Analysis</i> , 6(2):465-476 (1998).	—
<i>GW</i>	172	WENGENACK et al., "Targeting Alzheimer amyloid plaques in vivo," <i>Nature Biotech.</i> , 18:868-824 (2000).	—
<i>GW</i>	219	WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <i>Proc. Natl. Acad. Sci. USA</i> , 82:8729-8732 (1985).	—
<i>GW</i>	173	WOOD et al., "Amyloid precursor protein processing and A β 42 deposition in a transgenic mouse model of Alzheimer disease," <i>PNAS</i> , 94: 1550-1555 (1997).	—
	174	Human Immunology & Cancer Program brochure, from The University of Tennessee Medical Center/Graduate School of Medicine, Knoxville, Tennessee (publication date unknown). <i>GW</i>	—

Examiner
SignatureDate
Considered

11/15/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3189626 v1

DEC 11 2001
USPTO
OIPC
SEARCHED